Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition

Background. The present study evaluates outcome after chemoradiotherapy (CRT) with concurrent and/or sequential Programmed Cell Death 1 (PD-1) or Ligand 1 (PD-L1) immune checkpoint inhibition (CPI) for inoperable stage III NSCLC patients depending on planning target volume (PTV). Method and patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Taugner, Julian, Käsmann, Lukas, Karin, Monika, Eze, Chukwuka, Flörsch, Benedikt, Guggenberger, Julian, Li, Minglun, Tufman, Amanda, Reinmuth, Niels, Duell, Thomas, Belka, Claus, Manapov, Farkhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763767/
https://www.ncbi.nlm.nih.gov/pubmed/34351518
http://dx.doi.org/10.1007/s10637-021-01143-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763767/
https://www.ncbi.nlm.nih.gov/pubmed/34351518
http://dx.doi.org/10.1007/s10637-021-01143-0

Ejemplares similares